UK – MHRA drafts mRNA cancer immunotherapy guidance
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is seeking input on its draft guidance for developing individualized messenger ribonucleic acid (mRNA) cancer immunotherapies. The agency said that research into the treatments is advancing rapidly, and it wants to ensure its premarket pathways are prepared to allow such products on the market.
Since the technology was successfully used to develop COVID-19 vaccines, drugmakers have sought to apply it in new therapeutic areas, with oncology being a major focus.
More information on Regulatory Focus and on the Medicines & Healthcare products Regulatory Agency Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (26 mars 2025). UK – MHRA drafts mRNA cancer immunotherapy guidance. ELSIBI. Consulté le 12 octobre 2026 à l’adresse https://doi.org/10.58079/13knj
